(Q44537811)

3 December 2017

The importance of being seizure free: topiramate and psychopathology in epilepsy (English)

1 reference

3 December 2017

1 reference

1

1 reference

3 December 2017

Michael R Trimble

2

1 reference

3 December 2017

1 August 2003

1 reference

3 December 2017

1 reference

3 December 2017

4

1 reference

3 December 2017

4

1 reference

3 December 2017

430-434

1 reference

Psychiatric syndromes related to antiepileptic drugs

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Postmarketing experience with topiramate and cognition

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Topiramate and psychiatric adverse events in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Vigabatrin and psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Vigabatrin and behaviour disorders: a retrospective survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Forced normalization at the interface between epilepsy and psychiatry.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Topiramate monotherapy in adults with newly diagnosed epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Topiramate monotherapy for childhood absence seizures: an open label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Psychiatric complications in patients with epilepsy: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Clinical presentations in neuropsychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Factors associated with behavioral and cognitive abnormalities in children receiving topiramate.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Atypical antipsychotics and serotoninergic antidepressants in patients with epilepsy: pharmacodynamic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Epilepsy, psychosis and clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Antiepileptic-antipsychotic drug interactions: a critical review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

On the use of tranquillisers in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Pharmacokinetic Interactions between Antiepileptic and Antidepressant Drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

Antidepressant and double antidepressant treatment for the affective disorder of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2803%2900145-8

7 January 2021

10.1016/S1525-5050(03)00145-8

Identifiers

DOI

1 reference

3 December 2017

1 reference

PubMed ID

12899865